SalubrisBio’s JK06 shows early promise, but can 5T4 ADCs move beyond niche excitement?
Find out how SalubrisBio’s JK06 data could reshape 5T4-targeted ADC development in lung and breast cancer.
Why Hologic’s Breast Cancer Index data matter for precision oncology beyond recurrence risk
Hologic’s Breast Cancer Index is changing endocrine therapy decisions. The bigger test is adoption in real-world breast cancer care.
Veracyte’s ASCO 2026 data could sharpen the commercial case for genomic cancer diagnostics
Veracyte’s ASCO data could sharpen the case for genomic testing in breast and prostate cancer. Read why adoption still faces hard tests.
Why AstraZeneca’s EMERALD-3 and SERENA-6 data could influence future standards of cancer care
Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.
Why Sapu Nano’s Deciparticle platform could become a broader oncology drug-delivery play
Discover how Sapu Nano’s Deciparticle platform could reshape oncology drug delivery and expand intravenous everolimus development.
Can ArteraAI Breast turn routine pathology slides into breast cancer risk intelligence?
AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.
How Agendia’s breast cancer assays are testing the limits of race-based clinical assumptions
Race matters in care access, but tumor biology may drive response. Agendia’s FLEX data sharpen the breast cancer equity debate.
Artera’s EU breakthrough in AI cancer testing opens a bigger battle over workflow, trust, and scale
Artera has won CE marking for its AI prostate and breast cancer assays. Read what this means for oncology diagnostics, adoption, and global expansion.
From lorlatinib to PF-08634404, how Pfizer is trying to reshape its oncology story at ASCO 2026
Pfizer’s ASCO 2026 oncology data span lorlatinib, talazoparib, tucatinib and new pipeline assets. Read what the updates could change next.
Can Hologic’s breast imaging AI close one of mammography’s most stubborn detection gaps?
Hologic’s latest breast imaging AI data suggests stronger detection of hard-to-find cancers. Read what it could mean for screening adoption.